{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:00:04Z","timestamp":1790715604941,"version":"4.1.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["C180501"],"award-info":[{"award-number":["C180501"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81461168030"],"award-info":[{"award-number":["81461168030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"China Ministry of Science and Technology National 973 Project","award":["2015CB910500"],"award-info":[{"award-number":["2015CB910500"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.antiviral.2016.07.015","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T07:20:16Z","timestamp":1469604016000},"page":"165-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["MERS-CoV spike protein: Targets for vaccines and therapeutics"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3768-0401","authenticated-orcid":false,"given":"Qihui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.07.015_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coviro.2014.06.002","article-title":"Antiviral drugs specific for coronaviruses in preclinical development","volume":"8","author":"Adedeji","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib2","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1128\/JVI.03427-14","article-title":"Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease","volume":"89","author":"Agrawal","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijid.2013.12.003","article-title":"Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study","volume":"20","author":"Al-Tawfiq","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00884-14","article-title":"Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia","volume":"5","author":"Alagaili","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2016.07.015_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1099\/0022-1317-1-2-175","article-title":"The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture","volume":"1","author":"Almeida","year":"1967","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1401505","article-title":"Evidence for camel-to-human transmission of MERS coronavirus","volume":"370","author":"Azhar","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.07.015_bib7","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1128\/JVI.01294-14","article-title":"Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus","volume":"88","author":"Baez-Santos","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib8","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1128\/JVI.79.14.8828-8834.2005","article-title":"A\u00a0human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates","volume":"79","author":"Barouch","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/v4061011","article-title":"Mechanisms of coronavirus cell entry mediated by the viral spike protein","volume":"4","author":"Belouzard","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2016.07.015_bib10","doi-asserted-by":"crossref","first-page":"20290","DOI":"10.2807\/ese.17.40.20290-en","article-title":"Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012","volume":"17","author":"Bermingham","year":"2012","journal-title":"Euro. Surveill."},{"key":"10.1016\/j.antiviral.2016.07.015_bib11","doi-asserted-by":"crossref","first-page":"14955","DOI":"10.1021\/bi00046a001","article-title":"A\u00a0trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein","volume":"34","author":"Blacklow","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2016.07.015_bib12","doi-asserted-by":"crossref","first-page":"105ra103","DOI":"10.1126\/scitranslmed.3002901","article-title":"A\u00a0neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge","volume":"3","author":"Bossart","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2016.07.015_bib13","doi-asserted-by":"crossref","first-page":"e1000642","DOI":"10.1371\/journal.ppat.1000642","article-title":"A\u00a0neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection","volume":"5","author":"Bossart","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2016.07.015_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00005-014-0322-x","article-title":"Human antibody production in transgenic animals","volume":"63","author":"Bruggemann","year":"2015","journal-title":"Arch. Immunol. Ther. Exp. Warsz."},{"key":"10.1016\/j.antiviral.2016.07.015_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0065-3519(99)80022-6","article-title":"Canine viral vaccines at a turning point - a personal perspective","volume":"41","author":"Carmichael","year":"1999","journal-title":"Adv. Veter Med. Ap"},{"key":"10.1016\/j.antiviral.2016.07.015_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"Carter","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib17","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1016\/j.vaccine.2007.02.050","article-title":"Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine","volume":"25","author":"Catanzaro","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2016.07.015_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1051\/vetres:2006055","article-title":"Coronavirus avian infectious bronchitis virus","volume":"38","author":"Cavanagh","year":"2007","journal-title":"Vet. Res."},{"key":"10.1016\/j.antiviral.2016.07.015_bib19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.antiviral.2016.07.015_bib20","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib21","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/infdis\/jiv325","article-title":"Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection","volume":"212","author":"Channappanavar","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2014.12.011","article-title":"Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus","volume":"115","author":"Cheng","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.07.015_bib23","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/jcb.21790","article-title":"Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors","volume":"104","author":"Chu","year":"2008","journal-title":"J.\u00a0Cell Biochem."},{"key":"10.1016\/j.antiviral.2016.07.015_bib24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3201\/eid1905.130057","article-title":"Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus","volume":"19","author":"Cotten","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fimmu.2013.00214","article-title":"Vaccine adjuvants: mode of action","volume":"4","author":"De Gregorio","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib26","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1128\/JVI.01244-13","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group","volume":"87","author":"de Groot","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib27","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.antiviral.2016.07.015_bib28","doi-asserted-by":"crossref","first-page":"16598","DOI":"10.1073\/pnas.1310744110","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques","volume":"110","author":"de Wit","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.015_bib29","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1021\/jm990154t","article-title":"Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1","volume":"42","author":"Debnath","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2016.07.015_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mib.2015.07.014","article-title":"Antibacterial monoclonal antibodies: the next generation?","volume":"27","author":"DiGiandomenico","year":"2015","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-921-1_1","article-title":"Therapeutic proteins","volume":"899","author":"Dimitrov","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib32","doi-asserted-by":"crossref","first-page":"e81587","DOI":"10.1371\/journal.pone.0081587","article-title":"A\u00a0truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines","volume":"8","author":"Du","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2016.07.015_bib33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV - a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib34","doi-asserted-by":"crossref","first-page":"9939","DOI":"10.1128\/JVI.01048-13","article-title":"Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development","volume":"87","author":"Du","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib35","first-page":"25","article-title":"The many mechanisms of viral membrane fusion proteins","volume":"285","author":"Earp","year":"2005","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib36","doi-asserted-by":"crossref","first-page":"E3179","DOI":"10.1073\/pnas.1217812110","article-title":"Conditionals by inversion provide a universal method for the generation of conditional alleles","volume":"110","author":"Economides","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.015_bib37","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1532-5415.1997.tb01474.x","article-title":"The 'common cold' in frail older persons: impact of rhinovirus and coronavirus in a senior daycare center","volume":"45","author":"Falsey","year":"1997","journal-title":"J.\u00a0Am. Geriatr. Soc."},{"key":"10.1016\/j.antiviral.2016.07.015_bib38","doi-asserted-by":"crossref","first-page":"e1004250","DOI":"10.1371\/journal.ppat.1004250","article-title":"Infection with MERS-CoV causes lethal pneumonia in the common marmoset","volume":"10","author":"Falzarano","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2016.07.015_bib39","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/srep01686","article-title":"Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin","volume":"3","author":"Falzarano","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2016.07.015_bib40","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-[alpha]2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2016.07.015_bib41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/cid\/cir334","article-title":"Clinical applications of DNA vaccines: current progress","volume":"53","author":"Ferraro","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib42","series-title":"Combating the Threat of Pandemic Influenza: Drug Discovery Approaches","first-page":"226","article-title":"Peptide inhibitors targeting virus-cell fusion in class I enveloped viruses","author":"Gao","year":"2007"},{"key":"10.1016\/j.antiviral.2016.07.015_bib43","doi-asserted-by":"crossref","first-page":"13134","DOI":"10.1128\/JVI.02433-13","article-title":"Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus","volume":"87","author":"Gao","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib44","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of modified vaccinia virus Ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2016.07.015_bib45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.aad1283","article-title":"An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels","volume":"351","author":"Haagmans","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2016.07.015_bib46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3181\/00379727-121-30734","article-title":"A\u00a0new virus isolated from the human respiratory tract","volume":"121","author":"Hamre","year":"1966","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.antiviral.2016.07.015_bib47","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.virol.2015.03.043","article-title":"Viral membrane fusion","volume":"479\u2013480","author":"Harrison","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2016.07.015_bib48","doi-asserted-by":"crossref","first-page":"967946","DOI":"10.1155\/2014\/967946","article-title":"A\u00a0computational approach for predicting role of human microRNAs in MERS-CoV genome","volume":"2014","author":"Hasan","year":"2014","journal-title":"Adv. Bioinforma."},{"key":"10.1016\/j.antiviral.2016.07.015_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(03)12162-9","article-title":"The common cold","volume":"361","author":"Heikkinen","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2016.07.015_bib50","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3201\/eid2007.140571","article-title":"MERS coronavirus in dromedary camel herd, Saudi Arabia","volume":"20","author":"Hemida","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib51","first-page":"805","article-title":"Coronavirus infections in working adults. Eight-year study with 229 E and OC 43","volume":"105","author":"Hendley","year":"1972","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib52","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1751-0813.2012.00978.x","article-title":"Coronavirus infection in intensively managed cattle with respiratory disease","volume":"90","author":"Hick","year":"2012","journal-title":"Aust. Vet. J."},{"key":"10.1016\/j.antiviral.2016.07.015_bib151","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/infdis\/jiw080","article-title":"Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV) -Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection","volume":"213","author":"Houser","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008140","article-title":"Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein","volume":"6","author":"Jiang","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2016.07.015_bib54","first-page":"345","article-title":"Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence","volume":"8","author":"Jiang","year":"1995","journal-title":"Pept. Res."},{"key":"10.1016\/j.antiviral.2016.07.015_bib55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/365113a0","article-title":"HIV-1 inhibition by a peptide","volume":"365","author":"Jiang","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.07.015_bib56","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.bcp.2012.08.012","article-title":"Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target","volume":"84","author":"Keum","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib57","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3201\/eid2107.150070","article-title":"MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013-2014","volume":"21","author":"Khalafalla","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrmicro1326","article-title":"Virus membrane-fusion proteins: more than one way to make a hairpin","volume":"4","author":"Kielian","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib59","doi-asserted-by":"crossref","first-page":"11955","DOI":"10.1128\/JVI.02105-13","article-title":"Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors","volume":"87","author":"Kilianski","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib60","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature17200","article-title":"Pre-fusion structure of a human coronavirus spike protein","volume":"531","author":"Kirchdoerfer","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.07.015_bib61","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/13543776.2013.823159","article-title":"Anti-SARS coronavirus agents: a patent review (2008-present)","volume":"23","author":"Kumar","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.antiviral.2016.07.015_bib62","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2016.07.015_bib63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dks458","article-title":"3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry","volume":"68","author":"Li","year":"2013","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2016.07.015_bib64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","article-title":"Peptide vaccine: progress and challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.antiviral.2016.07.015_bib65","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/cr.2015.113","article-title":"A\u00a0humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein","volume":"25","author":"Li","year":"2015","journal-title":"Cell Res."},{"key":"10.1016\/j.antiviral.2016.07.015_bib66","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2174\/156802606776287090","article-title":"Characterization and inhibition of SARS-coronavirus main protease","volume":"6","author":"Liang","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.antiviral.2016.07.015_bib67","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature11371","article-title":"Structural and genetic basis for development of broadly neutralizing influenza antibodies","volume":"489","author":"Lingwood","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.07.015_bib68","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1006\/viro.1996.0315","article-title":"Inhibition of feline immunodeficiency virus infection in\u00a0vitro by envelope glycoprotein synthetic peptides","volume":"220","author":"Lombardi","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2016.07.015_bib69","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature12328","article-title":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26","volume":"500","author":"Lu","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.07.015_bib70","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tim.2015.06.003","article-title":"Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond","volume":"23","author":"Lu","year":"2015","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib71","doi-asserted-by":"crossref","first-page":"10319","DOI":"10.1128\/JVI.00787-11","article-title":"Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design","volume":"85","author":"Lu","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib72","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/ncomms4067","article-title":"Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2016.07.015_bib73","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.micinf.2013.03.003","article-title":"Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection","volume":"15","author":"Lu","year":"2013","journal-title":"Microbes Infect."},{"key":"10.1016\/j.antiviral.2016.07.015_bib74","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.3390\/v6062392","article-title":"Alphavirus-based vaccines","volume":"6","author":"Lundstrom","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2016.07.015_bib75","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2014.02.004","article-title":"Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2016.07.015_bib76","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1016\/j.vaccine.2014.08.086","article-title":"Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-The importance of immunofocusing in subunit vaccine design","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2016.07.015_bib77","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature's pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.antiviral.2016.07.015_bib78","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/130.5.502","article-title":"Coronavirus infection in acute lower respiratory tract disease of infants","volume":"130","author":"McIntosh","year":"1974","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib79","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1073\/pnas.57.4.933","article-title":"Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease","volume":"57","author":"McIntosh","year":"1967","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.015_bib80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1742-4690-5-111","article-title":"Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm","volume":"5","author":"Melikyan","year":"2008","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2016.07.015_bib81","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3201\/eid2006.140402","article-title":"Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013","volume":"20","author":"Memish","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib82","doi-asserted-by":"crossref","first-page":"15214","DOI":"10.1073\/pnas.1407087111","article-title":"Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein","volume":"111","author":"Millet","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.015_bib83","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2014.11.021","article-title":"Host cell proteases: critical determinants of coronavirus tropism and pathogenesis","volume":"202","author":"Millet","year":"2015","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2016.07.015_bib84","doi-asserted-by":"crossref","first-page":"9379","DOI":"10.1128\/JVI.01277-13","article-title":"The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies","volume":"87","author":"Mou","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib85","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMc1215691","article-title":"Pneumonia from human coronavirus in a macaque model","volume":"368","author":"Munster","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.07.015_bib86","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.015_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7462","article-title":"A\u00a0synthetic consensus anti\u2013spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates","volume":"7","author":"Muthumani","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2016.07.015_bib88","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.virusres.2007.10.009","article-title":"SARS coronavirus accessory proteins","volume":"133","author":"Narayanan","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2016.07.015_bib89","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2741\/2191","article-title":"Peptide vaccines against cancer, infectious diseases, and conception","volume":"12","author":"Naz","year":"2007","journal-title":"Front. Biosci."},{"key":"10.1016\/j.antiviral.2016.07.015_bib90","doi-asserted-by":"crossref","first-page":"12489","DOI":"10.1128\/JVI.01845-13","article-title":"Middle East respiratory syndrome coronavirus accessory protein 4a is a Type I interferon antagonist","volume":"87","author":"Niemeyer","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib91","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00006454-200002000-00016","article-title":"Respiratory coronavirus infections in children younger than two years of age","volume":"19","author":"Nokso-Koivisto","year":"2000","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2016.07.015_bib92","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12539-015-0266-9","article-title":"Design of potential RNAi (miRNA and siRNA) molecules for Middle East respiratory syndrome coronavirus (MERS-CoV) gene silencing by computational method","volume":"7","author":"Nur","year":"2014","journal-title":"Interdiscip. Sci."},{"key":"10.1016\/j.antiviral.2016.07.015_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-1135(93)90126-R","article-title":"A\u00a0review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination","volume":"36","author":"Olsen","year":"1993","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib94","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1586\/14760584.2015.1036033","article-title":"Middle East respiratory syndrome: obstacles and prospects for vaccine development","volume":"14","author":"Papaneri","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2016.07.015_bib95","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1073\/pnas.1510830112","article-title":"Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection","volume":"112","author":"Pascal","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.015_bib96","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1086\/377612","article-title":"Coronavirus 229E-related pneumonia in immunocompromised patients","volume":"37","author":"Pene","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib97","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/14760584.2.2.197","article-title":"MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile","volume":"2","author":"Podda","year":"2003","journal-title":"Expert Rev. vaccines"},{"key":"10.1016\/j.antiviral.2016.07.015_bib98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.07.015_bib99","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.07.015_bib100","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1042\/BST0391371","article-title":"Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery","volume":"39","author":"Ramajayam","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.antiviral.2016.07.015_bib101","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1586\/erv.09.77","article-title":"DNA vaccines in veterinary use","volume":"8","author":"Redding","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2016.07.015_bib102","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0378-1135(93)90030-B","article-title":"Coronavirus immunogens","volume":"37","author":"Saif","year":"1993","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib103","series-title":"Coronaviruses with Special Emphasis on First Insights Concerning SARS","author":"Schmidt","year":"2005"},{"key":"10.1016\/j.antiviral.2016.07.015_bib104","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1517\/14712598.2011.608062","article-title":"A\u00a0review of palivizumab and emerging therapies for respiratory syncytial virus","volume":"11","author":"Shadman","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.antiviral.2016.07.015_bib105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.antiviral.2013.09.028","article-title":"Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research","volume":"100","author":"Simmons","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.07.015_bib106","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.vaccine.2012.11.096","article-title":"A\u00a0phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer","volume":"31","author":"Slovin","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2016.07.015_bib107","doi-asserted-by":"crossref","first-page":"11950","DOI":"10.1128\/JVI.01672-13","article-title":"Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies","volume":"87","author":"Song","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib108","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2016.07.015_bib109","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/S0140-6736(15)60859-5","article-title":"MERS in South Korea and China: a potential outbreak threat?","volume":"385","author":"Su","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2016.07.015_bib110","doi-asserted-by":"crossref","first-page":"E2018","DOI":"10.1073\/pnas.1402074111","article-title":"Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution","volume":"111","author":"Tang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.015_bib111","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/JVI.02009-15","article-title":"Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease","volume":"90","author":"Tao","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib112","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/bmj.1.5448.1467","article-title":"Cultivation of a novel Type of common-cold virus in organ cultures","volume":"1","author":"Tyrrell","year":"1965","journal-title":"Br. Med. J."},{"key":"10.1016\/j.antiviral.2016.07.015_bib113","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.antiviral.2016.07.015_bib114","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1086\/374222","article-title":"An outbreak of coronavirus OC43 respiratory infection in Normandy, France","volume":"36","author":"Vabret","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib115","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nbt822","article-title":"High-throughput engineering of the mouse genome coupled with high-resolution expression analysis","volume":"21","author":"Valenzuela","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib116","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00473-12","article-title":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans","volume":"3","author":"van Boheemen","year":"2012","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2016.07.015_bib117","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm1024","article-title":"Identification of a new human coronavirus","volume":"10","author":"van der Hoek","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2016.07.015_bib118","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2015.07.005","article-title":"Animal models of Middle East respiratory syndrome coronavirus infection","volume":"122","author":"van Doremalen","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.07.015_bib119","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1128\/JVI.00614-15","article-title":"Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein","volume":"89","author":"Volz","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature16988","article-title":"Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer","volume":"531","author":"Walls","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.07.015_bib121","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0006-291X(03)00197-9","article-title":"Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion","volume":"302","author":"Wang","year":"2003","journal-title":"Biochem. Bioph Res. Co."},{"key":"10.1016\/j.antiviral.2016.07.015_bib122","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1128\/AAC.00670-09","article-title":"ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation","volume":"53","author":"Wang","year":"2009","journal-title":"Antimicrob. Agents Ch."},{"key":"10.1016\/j.antiviral.2016.07.015_bib123","doi-asserted-by":"crossref","first-page":"7712","DOI":"10.1038\/ncomms8712","article-title":"Evaluation of candidate vaccine approaches for MERS-CoV","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2016.07.015_bib124","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2013.92","article-title":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4","volume":"23","author":"Wang","year":"2013","journal-title":"Cell Res."},{"key":"10.1016\/j.antiviral.2016.07.015_bib125","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.chom.2014.08.009","article-title":"Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26","volume":"16","author":"Wang","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2016.07.015_bib126","doi-asserted-by":"crossref","first-page":"10194","DOI":"10.1128\/JVI.74.21.10194-10201.2000","article-title":"Functional importance of the coiled-coil of the Ebola virus glycoprotein","volume":"74","author":"Watanabe","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib127","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1128\/CVI.00258-12","article-title":"Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults","volume":"19","author":"Wecker","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib128","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/978-1-4615-2996-5_73","article-title":"An overview of successful TGEV vaccination strategies and discussion on the interrelationship between TGEV and PRCV","volume":"342","author":"Welter","year":"1993","journal-title":"Coronaviruses"},{"key":"10.1016\/j.antiviral.2016.07.015_bib129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/10409230802058320","article-title":"Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme (vol. 43, pg 189, 2008)","volume":"43","author":"White","year":"2008","journal-title":"Crit. Rev. Biochem. Mol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib130","series-title":"Cumulative Number of Reported Probable Cases of Severe Acute Respiratory Syndrome (SARS)","author":"WHO","year":"2004"},{"key":"10.1016\/j.antiviral.2016.07.015_bib131","series-title":"Middle East Respiratory Syndrome Coronavirus (MERS-cov) \u2013 Update","author":"WHO","year":"2016"},{"key":"10.1016\/j.antiviral.2016.07.015_bib132","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chom.2015.09.013","article-title":"MERS, SARS, and Ebola: The role of super-spreaders in infectious disease","volume":"18","author":"Wong","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2016.07.015_bib133","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1128\/JVI.79.2.884-895.2005","article-title":"Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia","volume":"79","author":"Woo","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib134","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.virusres.2014.10.007","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein","volume":"194","author":"Xia","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2016.07.015_bib135","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.015_bib136","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.2174\/138161206779010369","article-title":"Drug design targeting the main protease, the Achilles' heel of coronaviruses","volume":"12","author":"Yang","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.antiviral.2016.07.015_bib137","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1099\/vir.0.059014-0","article-title":"Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease","volume":"95","author":"Yang","year":"2014","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib138","doi-asserted-by":"crossref","first-page":"9119","DOI":"10.1128\/JVI.01279-15","article-title":"Two mutations were critical for bat-to-human transmission of Middle East respiratory syndrome coronavirus","volume":"89","author":"Yang","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib139","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s13238-013-3096-8","article-title":"The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists","volume":"4","author":"Yang","year":"2013","journal-title":"Protein & Cell"},{"key":"10.1016\/j.antiviral.2016.07.015_bib140","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/infdis\/jit590","article-title":"An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus","volume":"209","author":"Yao","year":"2014","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.07.015_bib141","doi-asserted-by":"crossref","first-page":"8223","DOI":"10.1038\/ncomms9223","article-title":"Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody","volume":"6","author":"Ying","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2016.07.015_bib142","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1099\/0022-1317-83-3-623","article-title":"Six-helix bundle assembly and characterization of heptad repeat regions from the F protein of Newcastle disease virus","volume":"83","author":"Yu","year":"2002","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib143","doi-asserted-by":"crossref","first-page":"13133","DOI":"10.1038\/srep13133","article-title":"Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27","volume":"5","author":"Yu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2016.07.015_bib144","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.07.015_bib145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2015.03","article-title":"Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus","volume":"13","author":"Zhang","year":"2016","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.antiviral.2016.07.015_bib146","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/14760584.2014.912134","article-title":"Current advancements and potential strategies in the development of MERS-CoV vaccines","volume":"13","author":"Zhang","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.antiviral.2016.07.015_bib147","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/1743-422X-10-266","article-title":"A\u00a0safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV","volume":"10","author":"Zhao","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2016.07.015_bib148","doi-asserted-by":"crossref","first-page":"e0145561","DOI":"10.1371\/journal.pone.0145561","article-title":"Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with Middle East respiratory syndrome-coronavirus","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2016.07.015_bib149","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1073\/pnas.1323279111","article-title":"Rapid generation of a mouse model for Middle East respiratory syndrome","volume":"111","author":"Zhao","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.015_bib150","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1128\/JVI.80.2.891-899.2006","article-title":"Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies","volume":"80","author":"Zhu","year":"2006","journal-title":"J.\u00a0Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216301826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216301826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T22:23:23Z","timestamp":1656887003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216301826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":151,"alternative-id":["S0166354216301826"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.07.015","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MERS-CoV spike protein: Targets for vaccines and therapeutics","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}